卡维地洛治疗肝硬化门静脉高压症的作用机制及应用现状

何搏; 张春清

doi:10.3969/j.issn.1001-5256.2019.02.036

卡维地洛治疗肝硬化门静脉高压症的作用机制及应用现状

DOI: 10.3969/j.issn.1001-5256.2019.02.036

何搏,
张春清

山东大学附属省立医院消化内科

基金项目:

国家自然科学基金(81770606)；

详细信息

中图分类号: R575.21
计量
- 文章访问数: 2258
- HTML全文浏览量: 77
- PDF下载量: 450
- 被引次数: 0
出版历程
- 收稿日期: 2018-09-17
- 出版日期: 2019-02-20

Mechanism and current status of carvedilol in treatment of cirrhotic portal hypertension

Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University

Research funding:

摘要

摘要: 肝硬化门静脉高压症的形成依赖于肝内血管阻力的增加及血流高动力状态。卡维地洛因其特有的降低肝内血管阻力作用,理论上具有更好的降低门静脉高压的效果。归纳了卡维地洛降低门静脉高压已知及可能的机制,回顾了卡维地洛治疗肝硬化门静脉高压症的最新研究。认为卡维地洛有望成为治疗肝硬化门静脉高压症的核心药物,而他汀类药物可能成为其最佳搭档。
- 肝硬化 /
- 高血压,门静脉 /
- 卡维地洛 /
- 综述
Abstract: The formation of cirrhotic portal hypertension depends on the increase in intrahepatic vascular resistance and the state of hyperdynamic circulation. The specific effect of carvedilol in reducing intrahepatic vascular resistance has a better effect in alleviating portal hypertension in theory. This article summarizes the known and possible mechanisms of carvedilol in reducing portal hypertension and reviews the latest research advances in the role of carvedilol in the treatment of cirrhotic portal hypertension. It is pointed out that carvedilol is expected to become the core drug in the treatment of cirrhotic portal hypertension, and statins may be their best partner.
- liver cirrhosis /
- hypertension, portal /
- carvedilol /
- review

HTML全文

参考文献(25)

[1]HE CS, WU XJ.Influencing factors for long-term outcome of patients with esophagogastric variceal bleeding after transjugular intrahepatic portosystemic shunt[J/CD].Chin J Hepat Surg:Electronic Edition, 2018, 7 (2) :103-106. (in Chinese) 何长生, 吴性江.TIPS治疗食管胃底静脉曲张破裂出血长期疗效的影响因素[J/CD].中华肝脏外科手术学电子杂志, 2018, 7 (2) :103-106.

[2]ZHAO YL, LIU SS, YAO DJ, et al.Clinical study of transjugular intrahepatic portosystemic shunt for cirrhosis with portal hypertension[J].China Med Herald, 2018, 15 (28) :81-84. (in Chinese) 赵玉龙, 刘顺顺, 姚德炯, 等.经颈静脉肝内门体分流术治疗肝硬化门静脉高压症的临床研究[J].中国医药导报, 2018, 15 (28) :81-84.

[3]de FRANCHIS R.Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J].JHepatol, 2015, 63 (3) :743-752.

[4]ARAU'JO JU'NIOR RF, GARCIA VB, LEITO RF, et al.Carvedilol improves inflammatory response, oxidative stress and fibrosis in the alcohol-induced liver injury in rats by regulating kuppfer cells and hepatic stellate cells[J].PLo S One, 2016, 11 (2) :e0148868.

[5]HAMDY N, EL-DEMERDASH E.New therapeutic aspect for carvedilol:Antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage[J].Toxicol Appl Pharmacol, 2012, 261 (3) :292-299.

[6]DING Q, TIAN XG, LI Y, et al.Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-SrcERK signaling pathway[J].World J Gastroenterol, 2015, 21 (32) :9566-9576.

[7]REIBERGER T, FERLITSCH A, PAYER BA, et al.Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis[J].JHepatol, 2013, 58 (5) :911-921.

[8]DING Q, LI Z, LIU B, et al.Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action[J].J Clin Hepatol, 2017, 33 (3) :485-491. (in Chinese) 丁茜, 李振, 刘滨, 等.卡维地洛抑制血小板衍生因子BB诱导的人肝星状细胞活化和纤维化的作用机制[J].临床肝胆病杂志, 2017, 33 (3) :485-491.

[9]VILLANUEVA C, ALBILLOS A, GENESCJ, et al.Development of hyperdynamic circulation and response toβ-blockers in compensated cirrhosis with portal hypertension[J].Hepatology, 2016, 63 (1) :197-206.

[10]BHARDWAJ A, KEDARISETTY C, VASHISHTHA C, et al.Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis:A randomised placebo-controlled trial[J].Gut, 2017, 66 (10) :1838-1843.

[11]MANDORFER M, PECK-RADOSAVLJEVIC M, REIBERGERT.Prevention of progression from small to large varices:Are we there yet?An updated meta-analysis[J].Gut, 2017, 66 (7) :1347-1349.

[12]REIBERGER T, ULBRICH G, FERLITSCH A, et al.Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J].Gut, 2013, 62 (11) :1634-1641.

[13]SHARMA M, SINGH S, DESAI V, et al.Comparison of therapies for primary prevention of esophageal variceal bleeding:Asystematic review and network meta-analysis[J].Hepatology, 2018.[Epub ahead of print]

[14]LI J, SUN DJ, WANG GC, et al.A comparative analysis of carvedilol and propranolol in hepatic venous pressure gradient reduction in patients with cirrhotic portal hypertension[J].JClin Hepatol, 2016, 32 (1) :114-118. (in Chinese) 李晶, 孙东杰, 王广川, 等.卡维地洛与普萘洛尔降低肝硬化门静脉高压患者肝静脉压力梯度效果的对比分析[J].临床肝胆病杂志, 2016, 32 (1) :114-118.

[15]XU HH.Prophylactic efficacy of carvedilol and propranolol for first esophageal and gastric variceal bleeding in cirrhotic patients[J].J Prac Hepatol, 2018, 21 (5) :673-676. (in Chinese) 许红华.卡维地洛与普萘洛尔预防肝硬化并发食管静脉曲张首次破裂出血疗效比较[J].实用肝脏病杂志, 2018, 21 (5) :673-676.

[16]SHAH H, AZAM Z, RAUF J, et al.Carvedilol vs.esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage:A multicentre randomized controlled trial[J].JHepatol, 2014, 60 (4) :757-764.

[17]ABD ELRAHIM AY, FOUAD R, KHAIRY M, et al.Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding[J].Hepatol Int, 2018, 12 (1) :75-82.

[18]SCHWARZER R, KIVARANOVIC D, PATERNOSTRO R, et al.Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding:A dose-response study[J].Aliment Pharmacol Ther, 2018, 47 (8) :1162-1169.

[19]STANLEY A, DICKSON S, HAYES P, et al.Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding[J].JHepatol, 2014, 61 (5) :1014-1019.

[20]GUPTA V, RAWAT R, SHALIMAR N, et al.Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1month in patients with index variceal bleed:RCT[J].Hepatol Int, 2017, 11 (2) :181-187.

[21]YANG M.Clinical efficacy of carvedilol combined with endoscopic ligation in the treatment of cirrhotic esophageal varices[J].Prac J Clin Med, 2018, 15 (5) :139-141. (in Chinese) 杨明.卡维地洛联合内镜下套扎术治疗肝硬化食管静脉曲张临床疗效观察[J].实用医院临床杂志, 2018, 15 (5) :139-141.

[22]SINHA R, LOCKMAN KA, MALLAWAARACHCHI N, et al.Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites[J].J Hepatol, 2017, 67 (1) :40-46.

[23]LI HX, WANG G, WANG Z, et al.Relationship between the use of carvedilol and the improvement of survival of patients with liver cirrhosis ascites[J].J Prac Med, 2017, 33 (18) :3099-3102. (in Chinese) 李红艳, 王果, 王壮, 等.卡维地洛的使用与肝硬化腹水患者生存改善的相关性[J].实用医学杂志, 2017, 33 (18) :3099-3102.

[24]MANDORFER M, BOTA S, SCHWABL P, et al.Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis[J].Gastroenterology, 2014, 146 (7) :1680-1690.e1.

[25]WANI ZA, MOHAPATRA S, KHAN AA, et al.Addition of simvastatin to carvedilol non responders:A new pharmacological therapy for treatment of portal hypertension[J].World J Hepatol, 2017, 9 (5) :270-277.

施引文献

资源附件(0)

访问统计